Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05428449 · ClinicalTrials.gov registry record · Phase 1
Study in Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of GT20029
A Phase 1 study, sponsored by Suzhou Kintor Pharmaceutical Inc,.
- Completed
- Registry status
- Phase 1
- Development phase
- 123
- Enrollment target
NCT05428449 is a Phase 1 study that has completed, run by Suzhou Kintor Pharmaceutical Inc,. The registered enrollment target is 123 participants.
The verdict
NCT05428449, a Phase 1 study, has completed, sponsored by Suzhou Kintor Pharmaceutical Inc,.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 123 participants
- Enrollment target
Study Summary
A randomized, double-blind, placebo-controlled, parallel group, dose escalation study to evaluate the safety, tolerability and pharmacokinetics (PK) of GT20029 following topical single ascending dose in healthy subjects and multiple ascending dose administration in subjects with androgenetic alopecia(AGA) or acne
Interventions
- DRUG GT20029 Gel
- DRUG GT20029 Gel Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2022-02-10 |
| Est. Completion | 2023-04-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05428449
The ClinicalTrials.gov registry entry for NCT05428449 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 123 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Suzhou Kintor Pharmaceutical Inc,, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which GT20029 Gel is the first listed.
NCT05428449 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05428449 about?
NCT05428449 is a clinical study titled "Study in Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of GT20029". A randomized, double-blind, placebo-controlled, parallel group, dose escalation study to evaluate the safety, tolerability and pharmacokinetics (PK) of GT20029 following topical single ascending dose in healthy subjects and multiple ascending dose administration in subjects with androgenetic alopeci...
What is the current status of trial NCT05428449?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 123 participants. The study started on 2022-02-10. Estimated completion is 2023-04-06.
What interventions are being tested in trial NCT05428449?
The interventions under investigation include: GT20029 Gel (DRUG), GT20029 Gel Placebo (DRUG).
Who is sponsoring clinical trial NCT05428449?
This trial is sponsored by Suzhou Kintor Pharmaceutical Inc,, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.